EyePoint Pharmaceuticals (EYPT) Earnings Dates, Call Summary & Reports

Compare

993 Followers

Earnings Data

Report Date

May 06, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.8

Last Year’s EPS

-0.65

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 6 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 04, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents a constructive clinical and commercial story centered on rapid Phase 3 progress (wet AMD readouts mid-2026, DME pivotal dosing underway), a differentiated multi-mechanistic asset with promising Phase 2 efficacy and a clean safety profile in ~190 patients, along with manufacturing and commercial hires to support a potential launch. Offsetting these positives are material financial headwinds from sharply lower quarter and year revenues, substantially higher operating expenses and an increased net loss, with cash down year-over-year though raised financing provides runway into 2027. Regulatory/commercial execution and continued safety monitoring remain key near-term risks. Overall, the positive clinical momentum and adequate near-term funding tip the balance toward a favorable outlook despite clear financial burn and execution risks.

Company Guidance

EyePoint’s guidance and milestones were detailed and metric‑rich: top‑line Phase 3 wet AMD data from Lugano (with LUCIA closely following) is expected beginning mid‑2026 (next DMC safety review in May), and two pivotal DME Phase 3 trials (COMO and CAPRI) have begun randomization with first patients dosed last week, enrollment expected to complete in 2026 and top‑line DME data anticipated in 2027; cash and investments totaled $306M at 12/31/2025 (down from $371M a year earlier) after a $173M follow‑on in October, and management expects this to fund operations into 2027 and fully fund the DME program and NDA preparation for wet AMD; Q4 2025 revenue was $0.6M (Q4 2024: $11.6M) and FY revenue $31M (2024: $43M); Q4 OpEx $71M (vs $57M), FY OpEx $275M (vs $189M); Q4 net loss ~ $68M, $0.81/sh (vs $41M, $0.64), FY net loss $232M, $3.17/sh (vs $131M, $2.32); net non‑operating income was $3M in Q4 and $12M for the year; clinical metrics include >190 patients treated across four completed trials with no drug‑attributed ocular/systemic SAEs, cataracts of 5.8% in the 191‑patient database (DAVIO‑2 arms ~8%, aflibercept ~9%), floaters 5.2%, DAVIO‑2 unsupplemented treated eyes gained ~2.1 letters vs control, VERONA showed ~4–5 letter early separation and ~40 µm CST benefit at week 4, insert payload ~94% drug/6% matrix, vorolanib JAK1 IC50 ≈80 nM, ~140 global sites planned across the DME studies, Phase 3 dosing uses two inserts with an expected first‑year injection burden of two DuraVu vs five aflibercept (a theoretical 60% reduction if no supplementation; ~40% reduction using DAVIO‑2 supplementation rates), and a 41,000 sq ft cGMP facility with ~60 FTEs is online supporting CMC and commercial supply.

Advancing DuraVu into Phase 3 across key indications

Pivotal programs progressing: two Phase 3 wet AMD trials (Lugano and LUCIA) ongoing with top-line data expected beginning mid-2026; first patients dosed last week in both pivotal Phase 3 DME trials (COMO and CAPRI) with top-line DME data anticipated in 2027.

Strong Phase 2 efficacy signals and differentiated MOA

Phase 2 data (VERONA, DAVIO-2) showed durable single-dose efficacy, early separation vs aflibercept (as early as week 4: ~4–5 letters better and ~40 microns drier in VERONA), and potential six-month redosing. DuraVu's multi-mechanistic profile inhibits VEGF, PDGF and IL-6 via JAK1 (no Tie2 inhibition), supporting claims of faster onset and potential improved long-term outcomes.

Favorable safety profile across clinical program

No ocular or systemic SAEs attributed to DuraVu across >190 (191) treated patients in one Phase 1 and three Phase 2 trials; overall cataract incidence 5.8% (DAVIO-2 treatment arm ~8% vs EYLEA ~9%), vitreous floaters 5.2%, vitreous opacity ~1% in DAVIO-2, and only two mild cases of iritis (~1%) that resolved with topical therapy.

Commercial and manufacturing readiness

Commercial leadership strengthened with hire of experienced CCO Michael Campbell; 41,000 sq ft cGMP manufacturing facility in Northbridge, MA online >1 year with ~60 full-time employees supporting CMC submission and commercial supply and preparing for pre-approval inspection.

Robust global clinical infrastructure and investigator support

DME programs planned as global studies with ~140 sites across COMO and CAPRI, leveraging the wet AMD network; all invited wet AMD sites agreed to participate in DME studies, indicating investigator confidence and expected rapid enrollment.

Solid near-term capital position to fund operations

Cash and investments of $306 million as of 12/31/2025 (following a $173 million follow-on financing in October 2025) expected to fund operations into 2027 and fully support Phase 3 wet AMD NDA preparation and pivotal DME programs.

Statistically powered trial design with meaningful treatment-burden endpoint

Wet AMD trials use on-label aflibercept controls and noninferiority design; treatment-burden secondary endpoint measured after loading dose (DuraVu mandated 2 injections vs aflibercept 5 in year 1 = theoretical 60% reduction; applying DAVIO-2 supplementation rates implies ~40% reduction). Study is powered to detect treatment-burden differences as small as ~7–10%.

EyePoint Pharmaceuticals (EYPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EYPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2026	2026 (Q1)	-0.80 / -	-0.65	―	―	―
Mar 04, 2026	2025 (Q4)	-0.75 / -0.81	-0.64	-26.56% (-0.17)	―
Nov 05, 2025	2025 (Q3)	-0.77 / -0.85	-0.54	-57.41% (-0.31)	―
Aug 06, 2025	2025 (Q2)	-0.82 / -0.85	-0.58	-46.55% (-0.27)	―
May 07, 2025	2025 (Q1)	-0.67 / -0.65	-0.55	-18.18% (-0.10)	―
Mar 05, 2025	2024 (Q4)	-0.49 / -0.64	-0.33	-93.94% (-0.31)	―
Nov 07, 2024	2024 (Q3)	-0.55 / -0.54	-0.33	-63.64% (-0.21)	―	―
Aug 07, 2024	2024 (Q2)	-0.51 / -0.58	-0.61	4.92% (+0.03)	―	―
May 08, 2024	2024 (Q1)	-0.40 / -0.55	-0.56	1.79% (+0.01)	―	―
Mar 07, 2024	2023 (Q4)	-0.49 / -0.33	-1.16	71.55% (+0.83)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EYPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 04, 2026	$18.32	$18.00	-1.75%
Nov 05, 2025	$12.39	$11.02	-11.06%
Aug 06, 2025	$10.89	$10.58	-2.85%
May 07, 2025	$6.25	$6.09	-2.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?

EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on May 06, 2026, TBA (Confirmed).

What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?

EyePoint Pharmaceuticals Inc (EYPT) earnings time is at May 06, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EYPT EPS forecast?

EYPT EPS forecast for the fiscal quarter 2026 (Q1) is -0.8.